Back to search
FDAFDA · Food and drugs·Recall number D-0116-2026

Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-08

Published November 5, 2025 · Recall initiated: October 15, 2025

Summary

FDA records drug Class II recall D-0116-2026, published November 5, 2025 and initiated October 15, 2025. Recalling firm: ProRx LLC; Status: Ongoing; Reported quantity: 8,310 vials; Lot: Lot Prorx051425-2, Lot Prorx051425-3 and Lot Prorx051425-4. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
ProRx LLC
Distributor
TX and UT
Lot
Lot Prorx051425-2, Lot Prorx051425-3 and Lot Prorx051425-4
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-08 recalled?

Yes. FDA published recall D-0116-2026 on November 5, 2025. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter